Abstract
Heart failure, a major symptom in the progression of cardiac hypertrophy, is a critical risk factor for cardiac death. A large body of research has investigated cardioprotective mechanisms that prevent or minimize hypertrophy, identifying a variety of specific peptide hormones, growth factors, and cytokines with cardioprotective properties. Recent investigation of the downstream effector pathways for these growth factors has identified molecules involved in the progression of cardiac hypertrophy and heart failure, including phosphoinositide 3-kinase (PI3K), Akt and mammalian target of rapamycin (mTOR). Using genetically modified transgenic or knockout mice and adenoviral targeting to manipulate expression or function in experimental models of heart failure, several investigators have demonstrated that the PI3K-Akt pathway regulates cardiomyocyte size, survival, angiogenesis, and inflammation in both physiological and pathological cardiac hypertrophy. In this review, we discuss the reciprocal regulation of PI3K, Akt and mTOR in cardiomyocytes and their association with cardiac disease.
Keywords: PI3K, Akt, mTOR, cardiac hypertrophy, heart failure, hypertrophy, reciprocal, cardiomyocytes, phosphoinositide, cardioprotective, rapamycin, heterodimers, tensin, hormones, fibrosis, phosphotyrosine, manganese
Current Pharmaceutical Design
Title: Phosphoinositide-3 Kinase Signaling in Cardiac Hypertrophy and Heart Failure
Volume: 17 Issue: 18
Author(s): Toshinori Aoyagi and Takashi Matsui
Affiliation:
Keywords: PI3K, Akt, mTOR, cardiac hypertrophy, heart failure, hypertrophy, reciprocal, cardiomyocytes, phosphoinositide, cardioprotective, rapamycin, heterodimers, tensin, hormones, fibrosis, phosphotyrosine, manganese
Abstract: Heart failure, a major symptom in the progression of cardiac hypertrophy, is a critical risk factor for cardiac death. A large body of research has investigated cardioprotective mechanisms that prevent or minimize hypertrophy, identifying a variety of specific peptide hormones, growth factors, and cytokines with cardioprotective properties. Recent investigation of the downstream effector pathways for these growth factors has identified molecules involved in the progression of cardiac hypertrophy and heart failure, including phosphoinositide 3-kinase (PI3K), Akt and mammalian target of rapamycin (mTOR). Using genetically modified transgenic or knockout mice and adenoviral targeting to manipulate expression or function in experimental models of heart failure, several investigators have demonstrated that the PI3K-Akt pathway regulates cardiomyocyte size, survival, angiogenesis, and inflammation in both physiological and pathological cardiac hypertrophy. In this review, we discuss the reciprocal regulation of PI3K, Akt and mTOR in cardiomyocytes and their association with cardiac disease.
Export Options
About this article
Cite this article as:
Aoyagi Toshinori and Matsui Takashi, Phosphoinositide-3 Kinase Signaling in Cardiac Hypertrophy and Heart Failure, Current Pharmaceutical Design 2011; 17 (18) . https://dx.doi.org/10.2174/138161211796390976
DOI https://dx.doi.org/10.2174/138161211796390976 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Micro-RNAs, Exercise and Cellular Plasticity in Humans: The Impact of Dietary Factors and Hypoxia
MicroRNA Anemia and Chronic Kidney Disease: Making Sense of the Recent Trials
Reviews on Recent Clinical Trials Role of NF-κB in the Regulation of Cytochrome P450 Enzymes
Current Drug Metabolism Radionuclide Imaging in Patients with Ischemic Heart Failure
Current Medical Imaging Antiplatelet Therapy in Children: Why So Different from Adults’?
Current Pharmaceutical Design Potential Therapeutic Targets for Neurodegenerative Diseases: Lessons Learned from Calorie Restriction
Current Drug Targets Conivaptan: Potential Therapeutic Implications in Heart Failure
Recent Patents on Cardiovascular Drug Discovery Basic Mechanisms in Atherosclerosis: The Role of Calcium
Medicinal Chemistry Therapeutic Potential of Inhibiting Brutons Tyrosine Kinase, (BTK)
Current Pharmaceutical Design Supplementation of Glutamine and Omega-3 Polyunsaturated Fatty Acids as a Novel Therapeutic Intervention Targeting Metabolic Dysfunction and Exercise Intolerance in Patients with Heart Failure
Current Clinical Pharmacology Therapeutic Agents Based on DNA Sequence Specific Binding
Current Topics in Medicinal Chemistry HLA Peptide-mediated Strategies for Modulation of Cellular and Humoral Immune Response in Transplantation
Current Pharmacogenomics Inflammaging and Proteases in Abdominal Aortic Aneurysm
Current Vascular Pharmacology The Yin and Yang of the Ghrelin Gene Products
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Aldosteronism in Heart Failure: A Proinflammatory / Fibrogenic Cardiac Phenotype. Search for Biomarkers and Potential Drug Targets
Current Drug Targets Purinergic (P2) Receptor Control of Lower Genitourinary Tract Function and New Avenues for Drug Action: An Overview
Current Pharmaceutical Design Optimizing the Management of Uncontrolled/Resistant Hypertension. The Importance of Sleep Apnoea Syndrome
Current Vascular Pharmacology Tumor-Receptor Imaging in Breast Cancer: A Tool for Patient Selection and Response Monitoring
Current Molecular Medicine Microbial Biotransformation: Recent Developments on Steroid Drugs
Recent Patents on Biotechnology Pleiotropic Effects of HDL: Towards New Therapeutic Areas for HDL-Targeted Interventions
Current Molecular Medicine